KeyPath™ MRSA/MSSA Blood Culture Test
The only accelerated BSI test reporting both MRSA and MSSA.
Both results are critical. Don't settle for half the answer.
Powerful knowledge – in time to save lives.
The KeyPath™ MRSA/MSSA Blood Culture Test enables clinicians to optimize therapy by identifying and determining methicillin resistance or susceptibility of Staphylococcus aureus directly from Gram-positive GPC or GPCC blood cultures in five-and-a-half hours – one, two, or more days faster than with standard AST testing. You need both results, MRSA and MSSA, fast.
Before KeyPath™, there was no FDA cleared method for reporting MSSA from a positive blood culture in less than about 2-3 days. However, an MSSA result is clinically urgent information. Research has shown a 69% lower mortality hazard for MSSA patients when switched from vancomycin empiric therapy to nafcillin or cefazolin.1
KeyPath™ is the first and only test that allows you to diagnose and differentiate MRSA and MSSA in a positive GPC or GPCC blood culture, one to two days faster than with traditional methods. KeyPath™ is a phenotypic, growth-based test, and has been demonstrated not to be affected by gene mutations. We encourage you to consider the potentially life-saving value of accelerated, phenotypic MRSA and MSSA results.
KeyPath™ is easy to use and requires no special equipment. Labs are finding that they can quickly incorporate it into their workflow. Watch the movie at the bottom of the page to see just how easy it is.
Benefits of MicroPhage KeyPath™ Bacterial Identification and Antibiotic Susceptibility Testing
- Key pathogen results one to two days faster than current methods
- Detects genetically mutated strains
- True Phenotypic AST results for confidence
- Facilitates earlier optimization of antimicrobial therapy
- Potential for improved patient outcomes, decreased hospital length of stay, and cost savings
- Simple – requires no special equipment or training
The Case for Accelerated Susceptibility Testing in the Era of Antibiotic Resistance whitepaper. Click here to download.
The KeyPath™ MRSA/MSSA Blood Culture Test – BT is FDA cleared in the U.S. for use with the following blood culture bottle types:
- BD BACTEC™ Plus Aerobic/F
- BD BACTEC™ Plus Anaerobic/F
The KeyPath™ MRSA/MSSA Blood Culture Test – BT bears the CE Mark in Europe for use with the following BD BACTEC™ bottle types:
The KeyPath™ MRSA/MSSA Blood Culture Test – BTA bears the CE Mark in Europe for use with the following BacT/ALERT® bottle types:
1 Schweizer et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infectious Diseases 2011 11:279.
2 Pfaller et al. J. Antimicrob. Agent. Chemother. (42): 1762-1770.
This test is both FDA-cleared and CE marked for sale within and outside the U.S
KeyPath Training Material and Resources